Effectiveness of a Multi-Component Smoking Cessation Support Programme (McSCSP) for Patients with Severe Mental Disorders: Study Design

Maria Paz Garcia-Portilla, Leticia Garcia-Alvarez, Pilar Alejandra Saiz, Eva Diaz-Mesa, Gonzalo Galvan, Fernando Sarramea, Josefa Garcia-Blanco, Edorta Elizagarate and Julio Bobes
Additional contact information
Maria Paz Garcia-Portilla: Departmento de Psiquiatría, Universidad de Oviedo, 33006 Oviedo, Spain
Leticia Garcia-Alvarez: Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Universidad de Oviedo, 33006 Oviedo, Spain
Pilar Alejandra Saiz: Departmento de Psiquiatría, Universidad de Oviedo, 33006 Oviedo, Spain
Eva Diaz-Mesa: Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Universidad de Oviedo, 33006 Oviedo, Spain
Gonzalo Galvan: Universidad Nacional de la Patagonia Austral, Puerto San Julián, 9310 Santa Cruz, Argentina
Fernando Sarramea: Complejo Hospitalario de Jaén, Equipo de Salud Mental de Andújar, 23740 Jaén, Spain
Josefa Garcia-Blanco: Complejo Hospitalario de Jaén, Equipo de Salud Mental de Andújar, 23740 Jaén, Spain
Edorta Elizagarate: Unidad de Psicosis Refractarias, Hospital Psiquiátrico de Álava, 01006 Vitoria, Spain
Julio Bobes: Departmento de Psiquiatría, Universidad de Oviedo, 33006 Oviedo, Spain

IJERPH, 2013, vol. 11, issue 1, 1-17

Abstract: Only a few studies have examined the efficacy and safety of smoking cessation programmes in patients with mental disorders. The aim of this paper is to describe in detail the methodology used in the study as well as the Multi-component Smoking Cessation Support Programme in terms of pharmacological treatments and psychological interventions. An open-label 9-month follow-up study was conducted in Spain. A total of 82 clinically stable outpatients with schizophrenia, schizoaffective or bipolar disorder were enrolled. Treatment consisted of a programme specifically developed by the research team for individuals with severe mental disorders. The programme consisted of two phases: (1) weekly individual motivational therapy for 4–12 weeks, and (2) a 12-week active treatment phase. During this phase, at each study visit patients received a one- or two-week supply of medication (transdermal nicotine patches, varenicline or bupropion) with instructions on how to take it, in addition to group psychotherapy for smoking cessation. Evaluations were performed: (1) at the time of enrolment in the study, (2) during the 12-week active treatment phase of the study (weekly for the first 4 weeks and then biweekly), and (3) after the end of this phase (two follow-up assessments at weeks 12 and 24). Evaluations included: (1) smoking history, (2) substance use, (3) psychopathology, (4) adverse events, and (5) laboratory tests. The importance of this study lies in addressing a topical issue often ignored by psychiatrists: the unacceptably high rates of tobacco use in patients with severe mental disorders.

Keywords: schizophrenia; bipolar disorder; transdermal nicotine patches; varenicline; bupropion (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/11/1/373/pdf (application/pdf)
https://www.mdpi.com/1660-4601/11/1/373/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:11:y:2013:i:1:p:373-389:d:31621

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().